^
Association details:
| Biomarker: | BAP1 mutation |
|---|---|
| Cancer: | Mesothelioma |
| Drug: | Lynparza (olaparib) (PARP inhibitor) |
| Direction: | Resistant |
Evidence:
Source:
Title:
Olaparib in Patients With HRD Malignant Mesothelioma
Excerpt:
...- Participant must show evidence of specific DNA changes/genetic mutations defined as follows: A) BAP1 loss (the loss of a protein called ubiquitin carboxyl-terminal hydrolase) verified by physicians at the University of Chicago using sampling tests AND/OR B) A mutation (abnormal change) in the participant's germ cells (reproductive cells) or somatic cells (non-reproductive cells) that disrupts protein function in at least one of the patient's genes....
Trial ID:
Source:
Title:
Olaparib in People With Malignant Mesothelioma
Excerpt:
...Percentage of Participants With Breast Cancer Type 1 Associated Protein-1 (BAP1) Somatic Mutations Who Experienced Partial or Complete Response.`...
Trial ID:
Less C2 evidence
Source:
Title:
Phase 2 Study of Olaparib in Malignant Mesothelioma and Correlation of Efficacy With Germline or Somatic Mutations in BAP1 Gene
Published date:
09/17/2021
Excerpt:
Olaparib has limited activity in previously treated mesothelioma including patients with BAP1 mutations. Germline BAP1 mutations were associated with decreased PFS and OS.
DOI:
10.1016/j.jtocrr.2021.100231
Source:
Title:
Phase II study of olaparib in malignant mesothelioma (MM) to correlate efficacy with germline and somatic mutations in DNA repair genes.
Published date:
05/13/2020
Excerpt:
Phase II single-center study (NCT03531840) enrolled patients with advanced pleural or peritoneal mesothelioma...Olaparib has limited anti-tumor activity in previously treated MM patients including those with germline or somatic BAP1 mutations. Presence of germline BAP1 mutations was associated with decreased PFS and OS.
DOI:
10.1200/JCO.2020.38.15_suppl.9054
Trial ID:
